Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia
- Written by ACN Newswire - Press Releases
TOKYO, Jun 2, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched its in-house discovered orexin receptor antagonist DAYVIGO (lemborexant) CIV for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance in the U.S. on June 1, 2020.Discovered
Read more //?#